Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Plus Tiragolumab in Esophageal Squamous Cell Carcinoma
NCT04540211Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2020
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 5
01
Overview
A Phase 3 trial of atezolizumab, tiragolumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Roche. Started Oct 2020; status: completed.
02
Drugs
atezolizumabtiragolumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04540211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540211.